Key facts today
Merck & Co. is acquiring U.K. firm Verona Pharma for $10 billion to diversify its drug portfolio as Keytruda's patent expires in 2028. Verona's COPD treatment shows strong sales potential.
Merck & Co. has begun Phase 3 trials for its monthly HIV prevention pill, MK-8527, advancing its global pre-exposure prophylaxis efforts.
Adagene Inc. will start patient enrollment for a Phase 2 trial in late 2025, testing its drug muzastotug with Merck's KEYTRUDA for colorectal cancer.
1,325 ARS
15.67 T ARS
58.58 T ARS
About Merck & Company, Inc.
Sector
Industry
CEO
Robert M. Davis
Website
Headquarters
Rahway
Founded
1891
ISIN
ARDEUT110277
FIGI
BBG000FSRB61
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Related stocks
MRK Buying Opportunity!MRK is currently undervalued. The stock price dropped approximately 45% from June 25th of last year to May 15th of this year. At present, the price has bounced off a long-term weekly trendline that has been respected since 2009, indicating a strong rejection zone.
Additionally, on the daily timefra
MRK Wave Analysis – 14 July 2025- MRK reversed from the support zone
- Likely to rise to resistance level 85.00
MRK recently reversed up from the support zone surrounding the long-term support level 73.45 (which has been reversing the price from the start of 2020, as can be seen from the weekly MRK chart below).
The upward rever
AAA - Setup from the bottomInverse head and shoulders pattern on the daily timeframe and if you were to break it down further to 12hr it should be also clear.
Monthly rsi sharply bounced back below an RSI of 30, weekly rsi has been below 30 rsi for multile touches
rsi line and rsi moving average crossover indicating change i
Merck Wave Analysis – 19 May 2025
- Merck reversed from support area
- Likely to rise to resistance level 80.00
Merck recently reversed up from the support area between the long-term support level 73.35 (which has been reversing the price from the middle of 2020) and the lower weekly Bollinger Band.
The upward reversal from this
Merck & Company Potential Post Tariff Resolution Bullish RallyWith potential developments towards the resolution of global tariffs and pharma being defensive in general, MRK price action seems to exhibit signs of a potential Bullish reversal breakout as the price action may form a prominent Higher High with multiple confluences through key Fibonacci and Suppor
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050Yield to maturity
7.34%
Maturity date
Jun 24, 2050
MRK5319197
Merck & Co., Inc. 2.9% 10-DEC-2061Yield to maturity
7.21%
Maturity date
Dec 10, 2061
US58933YBF1
MERCK & CO. 21/51Yield to maturity
7.15%
Maturity date
Dec 10, 2051
US58933YBA2
MERCK & CO. 20/40Yield to maturity
6.52%
Maturity date
Jun 24, 2040
US58933YAT2
MERCK CO. 2045Yield to maturity
6.40%
Maturity date
Feb 10, 2045
MRK4806294
Merck & Co., Inc. 4.0% 07-MAR-2049Yield to maturity
6.28%
Maturity date
Mar 7, 2049
MRK3900816
Merck & Co., Inc. 3.6% 15-SEP-2042Yield to maturity
6.18%
Maturity date
Sep 15, 2042
US58933YAJ4
MERCK CO. 13/43Yield to maturity
6.08%
Maturity date
May 18, 2043
MRK5584756
Merck & Co., Inc. 5.15% 17-MAY-2063Yield to maturity
6.04%
Maturity date
May 17, 2063
MRK5584755
Merck & Co., Inc. 5.0% 17-MAY-2053Yield to maturity
5.96%
Maturity date
May 17, 2053
MRK5584925
Merck & Co., Inc. 4.9% 17-MAY-2044Yield to maturity
5.82%
Maturity date
May 17, 2044
See all MRK bonds